Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV8102 in Advanced Solid Tumors
NCT03291002Phase 1Unknown
- Sponsor
- CureVac
- Start
- Sep 2017
- Primary completion
- Oct 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 5
01
Overview
Phase 1, open-label trial of CV8102 in melanoma, cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (HNSCC) and 1 more (4 cohorts), sponsored by CureVac. Primary endpoints: Dose determination for dose escalation cohorts at 2 weeks and Incidence of treatment related (Serious) Adverse Events up to 12 months. Status: unknown.
02
Drugs
CV8102
03
Conditions
melanomacutaneous squamous cell carcinoma (cSCC)head and neck squamous cell carcinoma (HNSCC)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03291002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291002.